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In the present study, the tissue content and functional effects of endothelin-1 
and endothelin-3 were examined in human vessels of importance in coronary 
bypass operations. Human coronary arteries (i.e., the left anterior descending 
coronary artery) were obtained from eight cardiac valve donors within 6 hours 
after death, pulmonary arteries were perioperatively obtained from 15 patients 
operated on because of lung tumors, and internal thoracic arteries and great 
saphenous and cephalic veins were obtained at coronary bypass operations 
from a total of 28 patients. Endothelin-1 and endothelin.3 content was 
quantified by radioimmunoassay. For functional experiments, the vessels were 
mounted in organ baths for recordings of isometric ontractions in response to 
endothelin-1, endothelin-3, and the endothelin A- receptor agonist sarafotoxin 
6c. In all vessels investigated, the endothelin-1 content was higher than that of 
endothelin-3. The highest levels were found in the left anterior descending 
coronary artery, followed in declining order by the internal thoracic artery, 
pulmonary artery, saphenous vein, and cephalic vein. Endothelin-1 contracted 
all vessels in a concentration-dependent fashion. This effect was enhanced in 
the left anterior descending and internal thoracic arteries by inhibition of 
nitric oxide and prostaglandin formation. The contractile ffect was attenuated 
in a concentration-dependent fashion in all vessels by incubation with the 
endothelinA-receptor blocker BQ-123. Furthermore, contractions evoked by 
endothelin-1 in the left anterior descending coronary and pulmonary arteries 
were antagonized by the combined endothelinA- and endothelinB-receptor 
blocker bosentan. Endothelin-3 contracted the left anterior descending coro- 
nary and pulmonary arteries and the saphenous vein, but not the internal 
thoracic artery, in a BQ-123-sensitive fashion. However, after inhibition with 
nitric oxide or prostaglandin, endothelin-3 also contracted the internal tho- 
racic artery, and the response in the left anterior descending coronary artery 
was enhanced. Sarafotoxin 6c evoked a BQ-123-sensitive contraction of the left 
anterior descending coronary artery. It is concluded that endothelin A receptors 
mediate the major portion of the vasoconstriction observed on exposure to 
endothelin-1, endothelin-3, and sarafotoxin 6c in the left anterior descending 
coronary, pulmonary, and internal thoracic arteries and the saphenous vein. 
Furthermore, endothelinB-receptor activation, with subsequent formation of 
nitric oxide or prostaglandin (or both), counteracts the vasoconstrictor re- 
sponse to endothelin in the left anterior descending coronary and internal 
thoracic arteries, but not in the pulmonary artery or saphenous vein. The 
present findings therefore suggest that endothelinA-receptor antagonism ight 
prove beneficial in preventing possible endothelin-induced coronary graft 
spasm. (J Thorac Cardiovasc Surg 1996;112:264-72) 
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T he endothelium is involved in the regulation of local vascular tone through release of both vaso- 
dilator and vasoconstrictor substances. 1 Experi- 
ments showing potent vasoconstrictor effects of me- 
dia obtained from cultured aortic endothelial cells 
suggested the existence of an endothelium-derived 
vasoconstrictor substance) The endothelium was 
later shown to synthesize the vasoactive peptide 
endothelin (ET) through enzymatic leavage of the 
propeptide big ET. 3 Studies have revealed a group 
of ET isopeptides named ET-1, ET-2, and ET-3. 4 
ET has been shown to evoke a variety of effects in 
the cardiovascular system, including vasoconstric- 
tion,3 vasodilatation,5, 6 and positive inotropic and 
chronotropic actions, 7' 8 as well as negative inotropic 
effects. 9 The variability of the effects of the three 
isopeptides in different vascular beds indicates the 
existence of multiple ET receptor subtypes. Thus 
the vascular effects of ET are mediated through 
interaction with putative ET A and ET B receptors. 
The ET A receptor is selective for ET-1 and causes 
vasoconstriction, whereas the ET B receptor is non- 
selective for the ET isopeptides and mediates vaso- 
dilatation] ° Recent reports in addition suggest he 
existence of ET B receptor subtypes: the ET m recep- 
tor on the endothelium mediates endothelium- 
dependent vasodilatation; the ETB2 receptor on 
smooth muscle cells causes vasoconstriction. 11' 12A 
family of snake venom peptides, the sarafotoxins, 
show a remarkable structural resemblance to ET 
and act on the same receptor as ET. 13 Among these 
peptides, sarafotoxin 6c is considered to activate 
ETB receptors. I1' 13 
A variety of pathophysiologic disorders are asso- 
ciated with increased circulating plasma levels of 
ET. It was recently demonstrated that the concen- 
tration of ET in the coronary sinus is increased 
during coronary bypass operations, 1< is although 
the mechanism of this release remains unclear, is 
Furthermore, ET is a potent constrictor of human 
coronary arteries 16 and of vessels used in coronary 
revascularization, 17 whereas ET causes a tone-de- 
pendent vasoconstriction or vasodilatation of pul- 
monary arteries. ~s In the present study, therefore, a
comparison of the functional effects of ET-1 and 
ET-3 on human coronary (i.e., left anterior descend- 
ing [LAD]), pulmonary (PA), and internal thoracic 
(ITA) arteries and great saphenous vein (SV) in 
vitro has been made. To further evaluate the influ- 
ence of ETB-receptor activation, we studied the 
effects of sarafotoxin 6c on the LAD and PA. In 
addition, the tissue content of ET-1 and ET-3 in 
these vessels and in the cephalic vein (CV) has been 
determined. 
Methods 
This study was approved by the Ethics Committee of 
the Karolinska Hospital. 
Functional experiments. Coronary arteries with an in- 
ner diameter of 0.8 to 1.2 mm (segments 7 and 8 of the 
LAD according to the American Heart Association Com- 
mittee Report, 1975) were obtained within 6 hours after 
death from eight cardiac valve donors (five men and three 
women, 33 + 7 years of age) with total cerebral infarction 
resulting from intracranial bleeding or trauma (or both). 
PAs of a similar size were obtained from 15 patients 
undergoing operations for lung tumors (10 men and five 
women, 67 -+ 3 years of age). Distal ITAs and SVs were 
obtained from 25 patients undergoing coronary artery 
bypass operations (16 men and nine women, 66 + 2 years 
of age). All vessels (1 to 2 mm in length) were dissected 
out under a microscope and mounted in 2 ml organ baths 
on two L-shaped holders (diameter 0.3 mm). A resting 
tension of 10 mN was then applied by adjusting one of the 
metal holders. The other holder was connected to a Grass 
polygraph model 7B (Grass Instrument Co., West War- 
wick, R.I.) for recordings of isometric tension. The resting 
tension was chosen on the basis of preliminary experi- 
ments in which reproducible contractions were obtained 
at this resting tension. 16 The vessels were kept in Tyrode's 
solution (pH 7.4) of the following composition (in milli- 
moles per liter): NaC1 37, KC1 2.7, CaC1 e 1.8, MgC12 1.05, 
NaHCO 3 11.9, NaH2PO 4 0.42, and glucose 5.6. The 
Tyrode's olution was aerated with 95% oxygen and 5% 
carbon dioxide at 37 ° C. After 60 minutes of equilibration 
during which the resting tension was adjusted to compen- 
sate for the spontaneous decline in arterial tension, circu- 
lar contractions were induced by Tyrode's solution in 
which the NaC1 had been replaced with equimolar 
amounts of KC1 to give a final K + concentration of 127 
mmol/L. Only vessels responding with two reproducible 
contractions toK + exposure were used, giving a total of 31 
LADs, 47 PAs, 29 ITAs, and 30 SVs. Each experimental 
procedure was performed in vessels from at least five 
patients. ET-1, ET-3, sarafotoxin 6c, or the ETB-receptor 
agonist Alai'3'11'~SET-1 m was added to the organ baths 
either at single concentrations or in a cumulative fashion. 
The functional effects of these agents were studied under 
control conditions and after ETa-receptor blockade using 
BQ-12319 or combined ET A and ET B blockade using 
bosentan. 12In addition, the effects of inhibition of pros- 
taglandin and nitric oxide formation were evaluated by 
incubating the vessels for 1 hour with the cyclooxygenase 
inhibitor indomethacin (10 5 mol/L) and the nitric oxide- 
synthase inhibitor Ng-monomethyl-L-arginine (L-NMMA; 
10 -4  tool/L), which were thereafter present hroughout 
the experiments. 18 Whereas BQ-123 and bosentan did not 
influence basal contractile tone per se, pretreatment with 
indomethacin and L-NMMA evoked a minor, but incon- 
sistent, increase in resting tension. 
Tissue determination f ET-1 and ET-3. Vessels were 
obtained from the above-mentioned patients and, in ad- 
dition, CV specimens were obtained from another two 
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Table I. Tissue content of ET-1 and ET-3 in some human vessels 
ET-1 ET-3 NPY CGRP 
LAD 1.14 -+ 0.13 0.27 _+ 0.05 9.7 + 1.33 2.48 -+ 0.17 
IMA 1.07 -+ 0.18 0.18 + 0.02 2.67 -+ 0.5 1.02 -+ 0.16 
PA  0.22 _+ 0.06 0.17 -+ 0.03 0.44 -+ 0.07 ND 
SV 0.21 -+ 0.02 0.05 -+ 0.01 4.62 -+ 1.14 0.22 -+ 0.03 
CV 0.17 -+ 0.03 0.07 -+ 0.03 ND 0.17 -+ 0.02 
For comparison the concentrations of neuropeptide Y (NPY) and calcitonin gene-related peptide (CGRP) have been determined. Levels are expressed as 
picomoles per gram and given as means _+ standard error of the mean (n = 2 to 22 in each group). 
ND, Not determined. 
patients (two women; 71 and 75 years old). The vessels 
were frozen on Dry Ice and weighed. For extraction of 
ET-I- and ET-3-1ike immunoreactivity, he samples were 
heated at 95 ° C in water for 10 minutes, homogenized, and 
centrifuged. With this eXtraction the recovery of ET in 
plasma is greater than 80%. 2° The supernatants were 
lyophilized and the content of ET-like immunoreactivity 
was determined by radioimmunoassay with two different 
antisera: ET-1 was determined by an ET-1 antiserum 
raised against ET-1 in rabbits (the cross-reactivity to ET-3 
was <8%); ET-3 was determined with a commercially 
available antiserum, RAS 6911 (Peninsula, Belmont, Ca- 
lif.), with less than 0.1% cross-reactivity to ET-1. None of 
the antisera used showed any cross-reactivity (<0.1%) to 
a variety of other peptides tested, including neuropeptide 
Y, angiotensins I, II, and III, neurokinin A, and calcitonin 
gene-related peptide. Human ET-1 or ET-3 labeled with 
iodine 125 was used as tracer and synthetic ET-1 or ET-3 
as standard. The assay samples were incubated at 4 ° C in 
phosphate buffer 0.1 mol/L, pH 7.4, containing 0.1% 
bovine serum albumin and 0.1% Triton X (Union Carbide 
Corp., Danbury, Conn.). The detection limit of the assays 
was 0.40 fmol/tube (for further details of the radioimmu- 
noassays, ee Hems6n and associates2°). For comparison, 
the tissue content of neuropeptide Y and calcitonin 
gene-related peptide, which are present in perivascular 
sympathetic and afferent nerve terminals, respectively, 
was determined. 21 
Drugs. ET-1, ET-3, BQ-123, Alal'3jXJSET-1, sarafo- 
toxin 6c, indomethacin, and L-NMMA were obtained from 
Peninsula Laboratories, Merseyside, England. Indometh- 
acin was dissolved in absolute ethanol and the other 
compounds were dissolved in saline solution. Bosentan 
was generously provided by Dr. M. Clozel, F. Hoffman-La 
Roche, Basel, Switzerland. 
Statistical evaluation. Values are given as means _+ 
standard error of the mean and expressed as percentage 
of contractions induced by a 127 mmol/L concentration f
K + in control experiments. For statistical evaluation, the 
Mann-Whitney U test was used; p < 0.05 was considered 
significant. 
Results 
Tissue content of ET-1 and ET-3. When quanti- 
fied by radioimmunoassay, the content of ET-1 
always exceeded that of ET-3 (Table I). The highest 
levels of both ETs were found in the LAD (1.14 _+ 
0.13 and 0.27 _+ 0.05 pmol/gm for ET-1 and ET-3, 
respectively), followed in declining order by the 
ITA, PA, SV, and CV. The concentration of neu- 
ropeptide Y was higher than that of the other 
peptides in all vessels investigated, whereas the 
distribution of calcitonin gene-related peptide more 
closely resembled that of ET-1 (Table I). 
Coronary arteries. Potassium (127 mmol/L) 
caused contractions of the coronary arteries 
amounting to 2.1 _+ 0.25 mN. Exposure to ET-1 
evoked a concentrat ion-dependent sustained con- 
traction of the arteries, which was markedly en- 
hanced in vessels incubated with L-NMMA and 
indomethacin (Fig. 1). Incubation with BQ-123 or 
bosentan (10 -6 to 10 -5 mol/L) shifted the concen- 
tration-response curve to ET-1 to the right with- 
out any significant influence on the maximal re- 
sponse (Figs. 2 and 3). ET-3 evoked a minor 
contraction of the LAD, which was slightly in- 
creased by indomethacin and L-NMMA (Fig. 4) 
and significantly and concentration-dependently 
reduced by BQ-123 (Fig. 5). Sarafotoxin 6c also 
evoked contractions of the LAD, which was sen- 
sitive to BQ-123 (Fig. 6) and bosentan (not 
shown). No contractile effects were observed for 
Alal,3,11JSET_1. 
PAs. The PAs responded with a strong and sus- 
tained contraction (1.74 _+ 0.26 raN) on exposure to 
potassium. ET-1 evoked a concentration-depen- 
dent, long-lasting contraction of the arteries that 
was not altered by incubation with L-NMMA and 
indomethacin (see Fig. 1). Incubation with BQ-123 
or bosentan (10 -6 to 10 -5 tool/L) caused a right- 
ward shift of the concentration-response curve (see 
Figs. 2 and 3). ET-3 also contracted the PA in a 
concentration-dependent manner (Fig. 4). This ef- 
fect was not influenced by incubation with indo- 
methacin and L-NMMA but was almost otally abol- 
ished after addition of BQ-123 (see Fig. 2). 
Sarafotoxin 6c in concentrations up to 10 -6 mol/L 
did not evoke contraction in any of the PAs inves- 
tigated (not shown). 
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Fig. L Contractile ffects of ET-1 in human LADs, PAs, ITAs, and SVs in control experiments (open 
squares) and after incubation with indomethacin 10 .5 mol/L and L-NMMA 10 -4  mol/L (black squares). 
Da'ta are presented as means + standard error of the mean and are expressed as percentage of the maximal 
contraction i duced by a 127 mmol/L concentration f K +. *p < 0.05, **p < 0.01, Mann-Whitney U test, 
compared with control experiments. 
ITAs. In the ITA potassium exposure voked a 
contraction of 1.34 +_ 0.22 raN. ET-1 caused a 
concentration-dependent contraction of the ITA, 
which was increased after indomethacin and L- 
NMMA incubation (see Fig. 1). Incubation with 
BQ-123, 10 .6 and 10 -s mol/L, significantly reduced 
the response to ET-1 (see Fig. 2). ET-3 did not per 
se evoke any contractions of the ITA. However, 
after incubation with indomethacin and L-NMMA, 
ET-3 evoked a sustained BQ-123-sensitive, concen- 
tration-dependent contraction of the ITA (see Figs. 
4 and 5). 
SVs. Potassium exposure caused a strong con- 
traction of the SV (3.06 ± 0.66 mN). Both ET-1 
and ET-3 induced concentration-dependent con- 
tractions of the SV, which were not affected by 
incubation with indomethacin and L-NMMA (see 
Figs. 1 and 4). After addition of BQ-123, the 
response:to ET-1 was shifted to the right, whereas 
the response to ET-3 was completely abolished 
(see Figs. 2 and 5). 
Discussion 
The important findings of this study are as fol- 
lows: (1) The content of ET-1 exceeded that of ET-3 
in all vessels investigated; (2) ET-induced contrac- 
tions of the vessels investigated are primarily caused 
by activation of ETA receptors; (3) neither prosta- 
glandin nor nitric oxide is produced in the SV or PA 
in response to ET, whereas production of both is 
induced in the ITA and LAD. 
The coronary and pulmonary levels of ET-l- l ike 
immunoreactivity detected in the present study are 
similar to those prcvious!y reported for total ET-like 
immunoreactivity. 2° The present study implies that 
the major portion of ET present in the vessels 
investigated is indeed ET-1. However, the use of an 
ET-3 antibody with no cross-reactivity to ET-1 
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clearly demonstrates that ET-3 is also found in 
human vessels, in agreement with studies on rat 
cardiopulmonary tissue. 22 However, because the 
vessels investigated were obtained from different 
patient groups with variability in age and sex, the 
relationship of ET content between the vessels 
should be interpreted with caution. 
Our study demonstrates that selective antagonism 
of ETA receptors may be used to reveal functional 
receptor populations within vessels. Evidence for 
heterogeneity of ET receptor distribution of human 
coronary arteries has been presented, z3It was sug- 
gested that the ET receptor population may differ 
within the same coronary vessel, with ETA receptors 
predominantly in distal preresistant coronary arter- 
ies, whereas both ET A and ET B receptors were 
present in larger, proximal coronary arteries. Ac- 
cording to the criteria used in that study, 23 all the 
coronary vessels used in the present study would be 
classified as preresistant; hus our study, demon- 
strating only ET A receptors, does not confirm the 
earlier findings. However, it may well be that the 
ET-receptor population and functional effects differ 
with vascular diameter within certain vascular beds. 
There are reports of ETB-mediated vasoconstriction 
of various vessels including canine and porcine 
coronary arteries, rabbit pulmonary arteries, and 
porcine PAs and pulmonary veins. 1°'24 The ET B 
receptor agonist sarafotoxin 6c was recently shown 
to contract the ITA, indicating the presence of 
contractile ET B receptors also in human arteriesY 
Interestingly, Davenport and associates 26could not 
demonstrate any contractile activity in human coro- 
nary or pulmonary arteries of BQ-3020 or 
Alal'3']~'15ET-1, two compounds with affinity for the 
ETB receptors. In contrast, 60% of the arteries 
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responded to sarafotoxin 6c. 27 In accord, we ob- 
served a concentration-dependent vasoconstriction 
of the LAD on exposure to sarafotoxin 6c but not 
Alal'3'll'ISET-1. Moreover, the response to sarafo- 
toxin 6c was attenuated equally by BQ-123 and 
bosentan. The magnitude of ET-1 contractions was 
twofold to fivefold greater than that of ET-3-in- 
duced contractions in the presently studied vessels, 
indicating that the observed vasoconstriction is me- 
diated predominantly by the ETa-receptor subtype. 
This is further substantiated by the competitive 
antagonism by the selective ETa-receptor blocker 
BQ-123 on the response to ET-1 and ET-3 in all 
investigated vessels. Although it has recently been 
reported that ETB-mediated vasoconstriction is
present in the pulmonary circulation of various 
species,lO, 24 no effects of sarafotoxin 6c were ob- 
served in the PA in the present study. Marked 
species differences are obviously present, but the 
receptor population may also differ in different 
vascular beds in the same species. Thus human 
kidney cortex contains ET A and ET B receptors in a 
30:70 ratio, 28 whereas the ratio in the human PA is 
93:7. 29 Finally, the selectivity of agonists and antag- 
onists is not absolute but depend on the concentra- 
tions used. 
It is likely that the vasodilatation and the putative 
vasoconstriction caused by activation of ET B recep- 
tors are mediated through different receptor sub- 
types, ET m and ETB2, present on the vascular 
endothelium and smooth muscle cells, respective- 
ly.n, 12 Subsequently, formation of prostacyclin or 
nitric oxide, or both, may counteract the vasocon- 
strictor effects of ETm-receptor activation. The 
presently observed response to ET-1 in the LAD 
was markedly enhanced after inhibition of prosta- 
LAD 
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Fig. 6. Contractile ffects of sarafotoxin 6c on LADs in 
control experiments (open triangles) and after incubation 
with BQ-123 at 10 -6 mol/L (black circles) or 10 -5 mol/L 
(black triangles). Data are presented as means + standard 
error of the mean and are expressed as percentage of the 
maximal contraction i duced by a 127 mmol/L concentra- 
tion of K +. *p < 0.05, **p < 0.01, Mann-Whitney U test, 
compared with control experiments. 
glandin and nitric oxide formation. Furthermore,  
ET-3 contracted the ITA  only after addit ion of 
indomethacin and L-NMMA. These findings suggest 
that format ion of prostacycl in or nitric oxide on 
ET- receptor  activation are important  determinants  
of the functional response to ET  exposure in the 
ITA  and LAD,  but not in the PA  or SV, although 
the investigated vessels respond to exogenous nitric 
oxide release from drugs such as nitroprus- 
side.18, 24, 25, 31 Both prostacycl in format ion and ni- 
tric oxide release are higher in the ITA  than in the 
SV. It is widely known that the ITA  has a higher 
capacity of endothe l ium-dependent  vasodi latat ion 
than does the SV. 3°' 31 The lack of influence of nitric 
oxide and prostaglandin i hibit ion on the ET  effect 
in the PA  is consistent with findings in porcine PAs 18 
and the report  that more than 90% of the ET  
receptors in the human lung belong to the ET  A 
subgroup. 29 
Auto logous graft vasospasm ay be an important  
factor in myocardia l  ischemia and postoperat ive 
morbidity after coronary revascular izat ion proce- 
dures. 3z The vasoconstr ictor pept ide ET  is known to 
be re leased uring bypass grafting 14' 15 and may play 
some role in the development  of vasospasm. On the 
basis of the present study, further investigation 
should be per fo rmed to evaluate whether  selective 
inhibit ion of ET A receptors may be clinically bene- 
ficial in preventing ET- induced graft spasm after 
cardiac operations.  
The technical assistance of M. Utahs, M. Runsi6, 
M. Stensdotter, and C. Nihl6n is gratefully acknowledged. 
REFERENCES 
1. Ltischer TF, Vanhoutte PM. Endothelium-dependent r - 
sponses in human blood vessels. Trends Pharmacol Sci 
1988;9:181-4. 
2. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Character- 
ization of a coronary vasoconstrictor p oduced by cultured 
endothelial cells. Am J Physiol 1985;248:C550-6. 
3. Yanagisawa M, Kiruhara H, Kimura S, et al. A novel potent 
vasoconstrictor peptide produced by vascular endothelial 
cells. Nature 1988;332:411-5. 
4. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyashi T, 
Goto K, et al. The human endothelin family: three structur- 
ally and pharmacologically distinct isopeptides predicted by 
three separate genes. Proc Natl Acad Sci 1989;86:2863-7. 
5. Lippton H, Goff J, Hyman A. Effects of endothelin i  the 
systemic and renal vascular beds in vivo. Eur J Pharmacol 
1988;155:197-9. 
6. Wright CE, Fozard JR. Regional vasodilatation is a promi- 
nent feature of the haemodynamic response to endothelin i
anaesthetized, spontaneously h pertensive rats. Eur J Phar- 
macol 1988;155:201-3. 
7. Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. 
Positive inotropic action of novel vasoconstrictor peptide 
endothelin on guinea-pig atria. Am J Physiol 1988;255: 
H970-3. 
8. Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. 
Positive chronotropic effects of endothelium: a novel endo- 
thelium-derived vasoconstrictor peptide. Pflugers Arch 1988; 
413:108-10. 
9. Franco-Cereceda A, Matran R, Lou Y-P, Lundberg J. Oc- 
currence and effects of endothelin i  guinea-pig cardiopul- 
monary tissue. Acta Physiol Scand 1990;137:539-47. 
10. Bax WA, Saxena PR. The current endothelin receptor clas- 
sification: time for reconsideration. Trends Pharmacol Sci 
1994;15:379-86. 
11. Warner TD, Allcock GH, Mickley EJ, Vane JR. Character- 
ization of endothelin receptors mediating the effects of the 
endothelin/sarafotoxin peptides on autonomic neurotrans- 
mission in the rat vas deferens and guinea-pig ileum. Br J 
Pharmacol 1993;110:783-9. 
12. Clozel M, Breu V, Gray GA, et al. Pharmacological charac- 
terization of bosentan, a new potent orally active nonpeptide 
endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 
270:228-35. 
13. Williams DL, Jones KL, Pettibone DJ, Lis EV, Clineschmidt 
BV. Sarafotoxin 6c: an agonist which distinguishes between 
endothelin receptor subtypes. Biochem Biophys Res Com- 
mun 1991;175:556-61. 
14. Franco-Ccreceda A, Ericsson A, Sellei P, Vaage J, Valen G, 
Lundberg JM. Endothelin release at reperfusion of the 
porcine ischaemic heart in relation to noradrenaline and 
neuropeptide Y. Acta Physiol Scand 1994;151:541-3. 
15. Franco-Cereceda A, Barr G, Owall A, Liska J, Lundberg JM. 
Is endothelin-1 release at reperfusion of the ischaemic hu- 
2 7 2 Holm and Franco-Cereceda 
The Journal of Thoracic and 
Cardiovascular Surgery 
August 1996 
man heart due to cold-induced isplacement of endothelin 
from binding sites? Eur J Pharmacol 1995;279:105-7. 
16. Franco-Cereceda A. ET- and NPY-induced vasoconstriction 
of human coronary arteries in vitro. Br J Pharmacol 1989;97: 
968-72. 
17. Costello K, Stewart D J, Baffour R. Endothelin is a potent 
constrictor of human vessels used in coronary revasculariza- 
tion surgery. Eur J Pharmacol 1990;186:311-4. 
18. Zellers TM, McCormick J, Wu Y. Interaction among ET-1, 
endothelium-derived nitric oxide, and prostacyclin i pulmo- 
nary arteries and veins. Am J Physiol 1994;267:H139-47. 
19, Ihara M, Nuguchi K, Saeki T, et al. Biological profiles of 
highly potent novel endothelin antagonists selective for the 
ET A receptor. Life Sci 1992;50:247-55. 
20. Hems6n A, Franco-Cereceda A, Matran R, Rudehill A, 
Lundberg JM. Occurrence, specific binding sites and func- 
tional effects of endothelin i  human cardiopnlmonary tissue. 
Eur J Pharmacol 1990;191:319-28. 
21. Franco-Cereceda A. Calcitonin gene-related peptide and 
human epicardial coronary arteries: presence, release and 
vasodilator effects. Br J Pharmacol 199I;102:506-10. 
22. Matsumoto H, Suzuki N, Onda H, Fujino M. Abundance of 
endothelin-3 in rat intestine, pituitary gland and brain. 
Biochem Biophys Res Commun 1989;164:74-80. 
23. Godfraind T. Evidence for heterogeneity of endothelin re- 
ceptor distribution i  human coronary arteries. Br J Pharma- 
col 1993;110:1201-5. 
24. Davenport AP, Maguire JJ. Is endothelin-induced vasocon- 
striction mediated only by ET A receptors in humans? Trends 
Pharmacol Sci 1994;15:9-11. 
25. Seo B, Oemar BS, Siebenmann R, Segesser L, Lfischer TF. 
Both ET A and ETB receptors mediate contraction to endo- 
thelin-1 in human blood vessels. Circulation 1994;89:1203-8. 
26. Davenport AP, O'Reilly G, Molenaar P, Maguire JJ, Kuc 
RE, Sharkey A, et al. Human endothelin receptors charac- 
terized using reverse transcriptase-polymerase chain reac- 
tion, in situ hybridization, and subtype-selective ligands BQ- 
123 and BQ-3020: evidence for expression of ETB receptors 
in human vascular smooth muscle. J Cardiovasc Pharmacol 
1993;22:$22-5. 
27. Maguire J J, Davenport AP. Endothelin-induced vasocon- 
striction in human isolated vasculature is mediated predom- 
inantly via activation of ETA receptors. Br J Pharmacol 
1993;110:47P. 
28. Nambi P, Pullen M, Wu HL, Aiyar N, Ohlstein EH, Edwards 
RM. Identification of endothelin-receptor subtypes in human 
renal cortex and medulla using subtype-selective ligands. 
Endocrinology 1992;131:1081-6. 
29. Fukuroda T, Kobayashi M, Ozaki S, et al. Endothelin recep- 
tor subtypes in human versus rabbit pulmonary arteries. J 
Appt Physiol 1994;76:1976-82. 
30. Sala A, Rona P, Pompilio G, et al. Prostacyclin production by 
different human grafts employed in coronary operations. Ann 
Thorac Surg 1994;57:1147-50. 
31. Pearson PJ, Evora PRB, Schaff HV. Bioassay of EDRF from 
internal mammary arteries: implications for early and late 
bypass graft patency. Ann Thorac Surg 1992;54:1078-84. 
32. Sarubu MR, McCtung JA, Fuss A, Reed GE. Early postop- 
erative spasm in left internal mammary artery bypass grafts. 
Ann Thorac Surg 1987;44:199-200. 
